SULJE VALIKKO

Englanninkielisten kirjojen poikkeusaikata... LUE LISÄÄ

avaa valikko

Oleg V. Borisov | Akateeminen Kirjakauppa

Haullasi löytyi yhteensä 3 tuotetta
Haluatko tarkentaa hakukriteerejä?



State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. - Monoclonal Antibody
John E. Schiel; Darryl L. Davis Davis; Oleg V. Borisov
Oxford University Press Inc (2016)
Kovakantinen kirja
170,80
Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Char
John E. Schiel; Darryl L. Davis; Oleg V. Borisov
Oxford University Press Inc (2016)
Kovakantinen kirja
195,40
Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3. - Defining the Next Ge
John E. Schiel; Darryl L. Davis; Oleg V. Borisov
Oxford University Press Inc (2016)
Kovakantinen kirja
195,40
Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. - Monoclonal Antibody
170,80 €
Oxford University Press Inc
Sivumäärä: 184 sivua
Asu: Kovakantinen kirja
Julkaisuvuosi: 2016, 21.04.2016 (lisätietoa)
Kieli: Englanti
Tuotesarja: ACS Symposium Series
Monoclonal antibodies (mAbs) are an important class of therapeutic that has greatly expanded our ability to treat a variety of indications, including cancer, autoimmune disorders, and infectious diseases. The cost of developing these molecules and ensuring that they are fit for purpose is much higher than for small-molecule drugs. Although some of these costs are due in part to the nature of production, a major cost is incurred because of the complexity of the
molecule itself. Extensive analytical testing regimes are needed for in-depth characterization and to ensure product stability, proper in-process controls, safety, and efficacy. The next generation of product understanding will require highly complex, orthogonal technologies to elucidate interdependent
structure-function relationships.

The ACS' focus on this field of research represents a defining moment in the development of technologies for characterizing mAbs. A multitude of experts in the field have come together around a single molecule for the first time to demonstrate both current and future practices involved in the characterization of a biotherapeutic. The current series presents an open discussion of current best practices, a multitude of intuitive research, and a collaborative philosophy on where the field needs to
move to satisfy future scientific and regulatory needs. Throughout this effort, a first-of-a-kind repository of regulatory considerations, experimental methods, and data-as well as a widely available "reference"-are now available to industry, academia, regulatory personnel, and instrument
manufacturers.

Tuotetta lisätty
ostoskoriin kpl
Siirry koriin
LISÄÄ OSTOSKORIIN
Tilaustuote | Arvioimme, että tuote lähetetään meiltä noin 4-5 viikossa | Tilaa jouluksi viimeistään 27.11.2024
Myymäläsaatavuus
Helsinki
Tapiola
Turku
Tampere
State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. - Monoclonal Antibody zoom
Näytä kaikki tuotetiedot
ISBN:
9780841230262
Sisäänkirjautuminen
Kirjaudu sisään
Rekisteröityminen
Oma tili
Omat tiedot
Omat tilaukset
Omat laskut
Lisätietoja
Asiakaspalvelu
Tietoa verkkokaupasta
Toimitusehdot
Tietosuojaseloste